论文部分内容阅读
目的探讨诱导疗法对急性髓系白血病患者临床疗效及生活质量的影响。方法选取2012年1月至2015年12月间在无锡市人民医院进行治疗的80例急性髓系白血病患者,回顾性分析患者采用标准剂量伊达比星联合阿糖胞苷诱导治疗的不良反应、疗效及复发情况。结果标准剂量伊达比星联合阿糖胞苷方案诱导治疗对造血系统的毒性为92.5%,对感染、脱发、胃肠道反应也有一定毒性影响。80例患者中,预后良好24例,预后中等50例,预后不良6例。预后良好患者在第1个疗程完全缓解率为54.2%,好于预后中等患者和预后不良患者,预后良好患者在各个疗程2年生存(OS)率以及2年无复发生存期(DFS)均明显高于预后中等患者。结论伊达比星联合阿糖胞苷诱导方案治疗急性髓系白血病患者生存状况明显优于常规治疗,有利于提高患者DFS和OS率,值得推广应用。
Objective To investigate the effect of induction therapy on clinical efficacy and quality of life in patients with acute myeloid leukemia. Methods Eighty patients with acute myeloid leukemia treated in Wuxi People’s Hospital from January 2012 to December 2015 were retrospectively analyzed. Adverse reactions induced by standard dose idarubicin combined with cytarabine were retrospectively analyzed. Efficacy and recurrence. Results The standard dose of combination of idarubicin and cytarabine was 92.5% toxic to the hematopoietic system and had some toxic effects on infection, alopecia and gastrointestinal reactions. In 80 patients, the prognosis was good in 24 cases, the prognosis was moderate in 50 cases, and the prognosis was poor in 6 cases. Patients with good prognosis in the first course of complete remission rate was 54.2%, better than the prognosis of moderate and poor prognosis patients with good prognosis in each course of 2-year survival (OS) rate and 2-year recurrence-free survival (DFS) were significantly Higher than the prognosis of moderate patients. Conclusion The survival of patients with acute myeloid leukemia treated with idarubicin and cytarabine is significantly better than that of routine treatment, which is beneficial to improve the DFS and OS rates. It is worth popularizing and applying.